Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b first-in-human (FIH) expansion cohort study of VIP152 in MYC-driven hematologic malignancies and solid tumors

Next Previous
Trial Profile

Phase 1b first-in-human (FIH) expansion cohort study of VIP152 in MYC-driven hematologic malignancies and solid tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enitociclib (Primary) ; Pembrolizumab (Primary)
  • Indications Advanced breast cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Lymphoma; Mantle-cell lymphoma; Neuroendocrine carcinoma; Ovarian cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Vincerx Pharma

Most Recent Events

  • 12 Nov 2021 According to a Vincerx Pharma media release,Arm 1 will enroll up to 40 patients with relapsed/refractory aggressive lymphoma, including DLBCL, transformed follicular lymphoma, and mantle cell lymphoma.Arm 2 will enroll up to 40 patients with advanced solid tumors, including patients with ovarian cancer, triple negative breast cancer, castration-resistant neuroendocrine prostate cancer, and any other solid tumor with MYC aberration.
  • 12 Aug 2021 According to a Vincerx Pharma media release, first patient had been dosed in this trial
  • 23 Apr 2021 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top